Singapore: Japan has confirmed a rise in dengue fever cases and the country's health ministry has said that with the rec...
Singapore: Alexion pharma has announced the submission of New Drug Application (NDA) to the Japanese Ministry of Health,...
Singapore: Japanese pharma major Takeda Pharmaceutical Company has announced that the randomized, double-blind, placebo-...
Singapore: Japan's pharmaceutical market value is set to grow at a compound annual growth rate (CAGR) of 1.3 percent fro...
Singapore: Eisai launched NerBloc Intramuscular Injection 2500 Units (botulinum toxin type B, "NerBloc"), a neuromuscula...
Singapore: Wyss Institute for Biologically Inspired Engineering at Harvard University has collaborated with Sony DADC, d...
Singapore: Takeda Pharmaceutical has submitted a new drug application (NDA) to the Japanese Ministry of Health, Labour a...
Singapore: Japan-based Ono Pharmaceuticals recently announced that the company has entered into an agreement with Gilead...
Singapore: Sanofi has been ranked third among 20 pharmaceutical companies on the 2012 Access to Medicine Index (ATM Ind...
Singapore: Akebia Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC)has announced that they have entered into ...
There is a fear that avian H5N1 virus could cause a pandemic of new influenza in humans without any warning. To prevent ...
Tokyo: Shionogi, one of Japan's century-old pharmaceutical manufacturers, has announced that its once-daily naldemedine ...
Tokyo: Japan's Asahi Kasei Chemicals and US-based SPI Pharma Inc. have agreed to form an alliance in the field of pharma...
Singapore: Aerocrine AB, a Swedish medical products company, has launched its marketing and sales efforts of Aerocrine's...
Singapore: The ministry of Health, Labor and Welfare (MHLW) in Japan has approved a drug for the treatment of patients w...
Singapore: The US FDA has recently given its approval for a device that treats dialysis-related amyloidosis (DRA), a com...
Singapore: Eisai announced that the US FDA has granted orphan drug designation to its investigational drug lenvatinib (...
Singapore: Pluristem Therapeutics, an Israel-based developer of placenta-based cell therapy products, has announced that...
